Objective To observe the clinical efficacy and safety of sildenafil in the treatment of high altitude heart disease associated with severe pulmonary arterial hypertension (PAH) in children. Methods Fifty children (aged 2 months to 2 years) with high altitude heart disease associated with severe PAH, who were continuously transferred to the Intensive Care Unit between January 2011 and October 2013, were randomly assigned to observation and control groups. The control group was given conventional treatment, while the observation group received oral sildenafil [1 mg/(kg·d)] three times daily for 7-10 days in addition to the conventional treatment. Before and after treatment, hemodynamics, blood gas, routine blood parameters, and blood biochemical parameters were recorded. Results After treatment, the observation group had a significantly higher decrease in mean pulmonary artery pressure and significantly higher increases in arterial partial pressure of oxygen, cardiac output, cardiac index, and oxygenation index compared with the control group (P<0.05). In the observation group, there were no significant changes in mean arterial pressure, routine blood parameters and blood biochemical parameters (P>0.05), and no obvious adverse reactions were found. Conclusions For children with high altitude heart disease associated with severe PAH, sildenafil can effectively reduce pulmonary artery pressure and improve cardiac function and does not cause adverse reactions. This therapy has good safety according to the preliminary evaluation.
Key words
Sildenafil /
High altitude heart disease /
Severe pulmonary arterial hypertension /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension[J]. N Engl J Med, 2005, 353(20): 2148-2157.
[2] 严晓娟, 马可忠, 刘海, 等. 西地那非治疗肺动脉高压的前 瞻性研究[J]．中国药房, 2012, 23(30): 2855-2857.
[3] 周正茂, 覃军, 黄岚, 等. 西地那非干预疑诊早期高原肺动 脉高压人群的临床研究[J]．第三军医大学学报, 2012, 34(6): 485-487.
[4] 第六届国际高原医学和低氧生理学术大会. 慢性高原病青海 诊断标准[J]. 青海医学院学报, 2005, 26(1): 3-5.
[5] 宋晓兰. 高原出生者重返高原致急性右心衰竭1 例[J]. 实用 儿科临床杂志, 2008, 23(24): 1881.
[6] 扇敏娜, 德吉美朵, 吴素兰. 拉萨地区汉族高原性心脏病婴 幼儿临床特征与电解质变化[J]. 实用儿科临床杂志, 2011, 26(13): 1054-1055.
[7] 冯宇，莫绪明. 西地那非治疗先天性心脏病伴肺动脉高压的 研究进展[J]. 中华临床医师杂志, 2011, 6(2): 426-428.
[8] Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hytertention: the UK Pulmonary Hypertension Srvice for Children 2001-2006[J]. Heart, 2009, 95(3): 312-317.
[9] Peiravian F, Amirghofran AA, Borzouee M, et a1. Oral sildenafil to control pulmonary hypertension after congenital heart surgery[J]. Asian Cardiovasc Thorac Ann, 2007, 15(2): 113-1l7.
[10] Namachivayam P, Theilen U, Butt WW, et a1. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children[J]. Am J Respir Crit Care Med, 2006, 174(9): 1042-1047.
[11] 陈仁伟, 周文武. 西地那非治疗儿童肺动脉高压的现状与进 展[J]. 临床小儿外科杂志, 2012, 11(2): 145-146.
[12] Pfizer Ltd. REVATIO U. S. Physician Prescribing Information 2007[EB/OL]. [2009-11]. http://media.pfizer.com/files/products/uspi_ revatio.pdf.
[13] 张颖, 刘双, 朱光发, 等. 西地那非治疗肺动脉高压的临床 疗效观察[J]. 心血管病杂志, 2011, 30(1): 20-24.
[14] 何翠瑶. 西地那非在儿童肺动脉高压的应用现状[J]. 中国当 代儿科杂志, 2010, 12(6): 509-511.
PDF(1303 KB)
